Crossmark

Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant Ube3a gene associated with Angelman syndrome

Crossref DOI link: https://doi.org/10.1186/s13229-018-0228-2

Published Online: 2018-08-17

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lee, Hyeong-Min

Clark, Ellen P.

Kuijer, M. Bram

Cushman, Mark

Pommier, Yves

Philpot, Benjamin D. http://orcid.org/0000-0003-2746-9143
Funding

Funding for this research was provided by:

National Institute of Neurological Disorders and Stroke (R01NS085093)

Angelman Syndrome Foundation

National Institutes of Health (P30CA023168)

National Cancer Institute (Z01-BC006161)
License Information

Text and Data Mining valid from 2018-08-17

Version of Record valid from 2018-08-17
More Information

Article History

Received: 14 March 2018

Accepted: 6 August 2018

First Online: 17 August 2018

Ethics approval and consent to participate

: Not applicable

: NCI has provided their consent to publish.

: Not applicable to authors except MC, who is on the Board of Directors and an investor in Gibson Oncology, Inc., which has licensed indenoisoquinoline intellectual property owned by Purdue University. Neither Gibson Oncology nor any other commercial company sponsored or provided other direct financial support to the author or his laboratory for the research reported in this article.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below